COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03720626
Expanded Access Status : Available
First Posted : October 25, 2018
Last Update Posted : March 10, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this Cohort Treatment Plan is to allow access to crizanlizumab (SEG101) for eligible patients diagnosed with sickle cell disease (SCD) to prevent or reduce the frequency of vaso-occlusive crises (VOC). The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Condition or disease Intervention/treatment
Sickle Cell Disease Drug: crizanlizumab

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Managed Access Program (MAP) to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients With History of Vaso-occlusive Crisis

Intervention Details:
  • Drug: crizanlizumab
    IV formulation with 30 min infusion, 5mg/kg dosage
    Other Name: SEG101

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

Written patient informed consent must be obtained prior to start of treatment.

  • Male or female, 18 to 70 years of age (inclusive) on the day of informed consent signature.
  • Confirmed diagnosis of sickle cell disease by hemoglobin electrophoresis or high performance liquid chromatography (HPLC) [performed locally]. All sickle cell disease genotypes are eligible (HbSS, HbSβ0, HbSC, HbSβ+, and others).
  • History of reoccurring VOC as assessed by the Treating Physician.
  • Patients receiving HU/HC, L-glutamine (Endari), erythropoietin stimulating agents or other therapies as prevention therapy and continue to experience VOC while on any of these treatments.
  • Patients can continue taking the preventive therapy.
  • Patient is not a candidate to be treated with alternative treatment options or has discontinued alternative treatments due to unacceptable benefit risk as documented by the Treating Physician.
  • Patient must meet the following laboratory values prior to treatment:
  • Absolute Neutrophil Count ≥1.0 x 109/L
  • Platelets ≥75 x 109/L
  • Hemoglobin (Hgb) ≥4.0 g/dL
  • Estimated glomerular filtration rate ≥ 45 mL/min
  • Direct (conjugated) bilirubin ≤2.0 x ULN
  • Alanine transaminase (ALT) ≤ 3.0 x ULN
  • ECOG performance status ≤ 2

Exclusion criteria

Patients eligible for this Treatment Plan must not meet any of the following criteria:

  • Is on a chronic transfusion program as defined by participating in a scheduled (pre-planned) series of transfusions (simple or exchange). Episodic transfusions are permitted.
  • Contraindication or hypersensitivity to any drug or metabolites from similar class as crizanlizumab drug or to any excipients of the drug formulation.
  • History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the Treating Physician may pose an increased risk of serious infusion reaction.
  • Use of therapeutic anticoagulation (prophylactic doses permitted) or antiplatelet therapy (other than aspirin or NSAIDs) within the 10 days prior to starting treatment
  • Patient has no acute pathologic processes.
  • Received a monoclonal antibody or immunomodulatory agent within 1 year of starting treatment, or has documented immunogenicity to a prior biologic.
  • Pregnant or nursing women
  • Patients with bleeding disorders
  • Known history of testing positive for Human Immunodeficiency Virus (HIV) infection
  • Patients with active Hepatitis B infections (HBsAg positive)

    o Note: Patients with antecedent but no active Hepatitis B (i.e. anti-HBc positive, HBsAg and HBV-DNA negative) are eligible

  • Significant active infection or immune deficiency (including chronic use of immunosuppressive drugs)
  • Has a serious mental or physical illness, which, in the opinion of the Treating Physician would compromise compliance to treatment.
  • QTcF ≥470 msec prior to treatment

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03720626

Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals

Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT03720626    
Other Study ID Numbers: CSEG101A2001M
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: March 2020
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Sickle cell disease
sickle cell anemia
vaso-occlusive crisis
monoclonal antibody
Anemia, Sickle Cell
HbS Disease
Hemoglobin SC Disease
Sickle Cell Disorders
Sickling Disorder Due to Hemoglobin S
Hb Sβ+-thalassemia
Hb Sβ0-thalassemia
Expanded Access Use
Pain Crisis
Compassionate Use
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn